18F-flurpiridaz Imaging for Heart Disease

Overseen By Barbara Blanchfield

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Akiva Mintz

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for known or suspected coronary artery disease (for detecting myocardial ischemia or infarction) detection and monitoring. The main question it aims to answer is:

Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-flurpiridaz and be imaged on a new type of high sensitivity PET scanner for up to 3 hours

Are You a Good Fit for This Trial?

This trial is for individuals with known or suspected coronary artery disease, including those who have had a heart attack or are healthy but at risk of heart disease. Participants will undergo an advanced PET scan using a new technique intended to significantly reduce radiation exposure.

Inclusion Criteria

I am 18 years old or older.

Ability to provide informed consent and comply with study procedures

I am not pregnant or breastfeeding, and if capable of bearing children, I have a negative pregnancy test.

Exclusion Criteria

More than four prior enrollments in this study

Inability to provide informed consent

Any condition that, in the investigator's judgment, may compromise participant safety or study integrity

What Are the Treatments Tested in This Trial?

Interventions

• 18F-flurpiridaz

Trial Overview

The study tests an ultralow dose PET imaging method using the radioactive tracer 18F-flurpiridaz on a high sensitivity scanner. The aim is to optimize timing and image quality while reducing radiation by up to 100 times compared to standard methods.

How Is the Trial Designed?

Group I: ultralow dose 18F-flurpiridaz imaging group Experimental Treatment 1 Intervention

Participants will be enrolled for an ultralow dose PET scan to evaluate image quality and optimize timing and reconstruction after reducing radiation doses 10-100 fold. Participants will be injected with a very small amount of radiotracer and imaged on a PET scanner for up to 3 hours

Who Is Running the Clinical Trial?

Akiva Mintz

Lead Sponsor

Trials

1

Recruited

40+